Prospective Multicenter Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients

Brief description of study

The purpose of this study is to demonstrate the effectiveness of Riociguat as replacement of PDE-5i therapy (Sildenafil or Tadalafil) in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i: Sildenafil or Tadalafil) with or without endothelin receptor antagonist (a drug that blocks endothelin receptors), but the treatment has not reached its goal. Riociguat (Brand name: Adempas) is approved by Health Authorities including the FDA (Food and Drug Administration) for the treatment of Pulmonary arterial hypertension.

Clinical Study Identifier: s18-02027

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.